The anticipated benefits of RIGENERA 2.0 trial for study participants are expected better LV function, a parameter that is well-known to influence long-term outcome. Nevertheless, chiefs of the different Units involved in the present study will form a Data Monitoring Committee that will stop the study in case of an observed increase in the rate of adverse events.